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In this issue of Cancer Cell, Phung and coworkers demonstrate that sustained endothelial activation of Akt by expression of 
constitutively activated Akt1 (myrAkt1) leads to blood vessels that essentially recapitulate the complex structural and functional 
abnormalities of tumor vessels. The authors provide evidence that rapamycin inhibition of PI3K/Akt/mTOR signaling in endothe-
lial cells (ECs), by either reducing Akt activity or blocking mTOR, reverses the pathologic effects associated with excess VEGF 
signaling in the tumor vasculature. However, unexpected findings following mTOR inhibition in vivo highlight the seemingly 
paradoxical and complex effects of rapamycin on various cell types within the tumor microenvironment.Despite decades of research on the 
process of neoplastic angiogenesis, the 
complex details of this dynamic process 
remain to be elucidated. Tumor angio-
genesis is mediated by a functional 
interplay of numerous proangiogenic 
and antiangiogenic molecules and their 
respective receptors, resulting in a net 
gain of proangiogenic signaling. Perhaps 
the most potent mediator of angiogen-
esis is vascular endothelial growth factor 
(VEGF/VEGF-A) (Hicklin and Ellis, 2005). 
Indeed, inhibition of VEGF activity has led 
to significant clinical benefit in a number of 
tumor types (Hurwitz et al., 2004; Motzer 
et al., 2006). In addition to being an endo-
thelial cell mitogen, VEGF also mediates 
a number of processes involved in angio-
genesis, including enhanced EC survival, 
increased vessel permeability, vasodilata-
tion, and regulation of pericyte coverage. 
The VEGF-A/VEGFR system signals in 
a PI3K/Akt-dependent manner, and this 
pathway is essential for many of the endo-
thelial alterations induced by VEGF/R sig-
naling (Gerber et al., 1998).
In this issue of Cancer Cell, Phung et 
al. (2006) investigated the role of EC Akt 
activation in mediating the abnormal struc-
ture and function of vasculature in tumors, 
likely due to VEGF-A. The authors dem-
onstrated that sustained endothelial acti-
vation of Akt by conditional expression of 
constitutively activated myristoylated Akt1 
(myrAkt1) led to the formation of enlarged 
and hyperpermeable blood vessels that 
essentially recapitulate the complex struc-
tural and functional abnormalities of tumor 
vessels, thought to be secondary to VEGF 
signaling. Moreover, the effects of Akt acti-
vation on the vascular bed are completely 
reversible upon reversal of Akt activation 
or with rapamycin treatment, suggesting 
that inhibition of EC Akt/mTOR signaling 
could be a promising approach for block-
ing the effects of tumor-derived angio-
genic factors such as VEGF-A. These 
findings clearly underline the importance 
of the PI3K/Akt/mTOR signaling pathway 
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esis. This has been recently exemplified 
in a phase III clinical trial with an mTOR 
inhibitor in patients with metastatic renal 
cell carcinoma (RCC), a highly angiogenic 
tumor (Hudes et al., 2006).
The elegant work by Phung and col-
leagues highlights several key issues. The 
use of PI3K/Akt/mTOR inhibitors appears 
to have an effect on the vascular network 
that is strikingly similar to that of VEGF/R 
inhibitors (at least in preclinical studies). 
It is possible that targeting this pathway 
will replicate or perhaps even comple-
ment current anti-VEGF agents. However, 
to make further progress in the field, it is 
essential to identify the factors that will be 
predictive of response to therapy. Despite 
the relative success with VEGF/R target-
ing, no validated predictive markers of effi-
cacy exist. The current study provides food 
for thought in regards to major mediators 
of VEGF signaling. One can hypothesize 
that the PI3K/Akt/mTOR pathway should 
be investigated in tumor-associated ECs 
to determine if this may be a predictive 
marker for anti-VEGF therapy.
The second important issue raised by 
this report is the validation of the abnor-
mal vascular network driven by VEGF and 
downstream signaling. The authors refer to 
utilizing rapamycin as an “antiangiogenic 
agent.” However, when EC signaling is 
inhibited, the formation of new blood vessel 
growth is not the only process being pre-
vented. In preclinical studies, anti-VEGF 
therapy or Akt/mTOR inhibition reverses 
the vascular abnormalities induced by 
tumors and, in turn, radically alters the 
function of the vascular network. Jain has 
termed this phenomenon “vascular nor-
malization” (Jain, 2005). This interesting 
hypothesis implies a paradoxical increase 
in blood flow and delivery of chemotherapy 
and oxygen to help explain why anti-VEGF 
therapy may augment the effects of che-
motherapy and radiotherapy. However, 
given the complexity of tumor biology and 
the fact that specific tumor systems have a r inc. differential and unique response to therapy, 
no single theory can explain the beneficial 
effects observed with anti-VEGF therapies. 
It is likely that anti-VEGF therapy and EC 
signaling inhibition exert different effects on 
the tumor vascular network in distinct tumor 
types; this may be dependent not only on 
tumor type, but also on site of tumor growth 
(metastatic site) as well as tumor size. In 
addition, anti-VEGF therapy may have 
a direct effect on tumor cells (Fan et al., 
2005). Thus, anti-VEGF therapy extends 
beyond effects on the vascular network.
Another key point highlighted by the 
Phung report is that the Akt/mTOR pathway 
is not a simple “linear” pathway. The current 
study reported on the use of a conditional 
knockin model where EC Akt signaling 
could be tightly controlled. Interestingly, 
inhibition of mTOR by rapamycin not only 
inhibited the downstream effects of acti-
vated endothelial Akt, but also reduced 
phosphorylation of myrAkt1 in ECs. This 
observation suggests that mTOR’s effects 
are both upstream and downstream in the 
Akt pathway. Rapamycin-mediated inhibi-
tion of endothelial Akt activity appeared 
to be critically dependent on the dose of 
rapamycin utilized; in vitro, lower doses of 
rapamycin actually led to an increase in Akt 
activation, whereas higher doses dimin-
ished Akt activation. Most interestingly, 
rapamycin led to paradoxical increases 
in Akt activation in tumor lysates at doses 
that inhibited Akt signaling in nonmalignant 
tissues, including ECs. However, rapamy-
cin significantly reduced tumor growth, 
suggesting that effects of rapamycin on 
EC cells and on signaling downstream 
of mTOR in tumor cells may override any 
tumor growth-promoting effects due to the 
increase in Akt phosphorylation.
Recently, rapamycin has been report-
ed to have variable effects on Akt activa-
tion in different models and different cell 
lines (Figure 1). In normal cells, insulin-like 
growth factor-I (IGF-I) and insulin-depen-
dent induction of the PI3K/Akt pathway 
leads to a mTOR/S6K-dependent feedback 89
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rapamycin modulates angiogenesis by two mechanisms: (1) inhibiting the mtOr/gβl/raptor complex 
in tumor cells, thus decreasing the production of vEgF, and (2) blocking Akt/mtOr signaling that is 
activated in response to vEgF in endothelial cells. Akt phosphorylation is regulated by Pi3K signaling 
and the mtOr/gβl/rictor complex. the effect of rapamycin on Akt phosphorylation is indirect and is 
dose and context dependent. in tumor lysates (in vivo), Akt activation is increased in tumor cells in 
response to rapamycin at doses that inhibit endothelial cell signaling. in vitro, rapamycin has a biphasic 
effect on Akt phosphorylation in endothelial cells; lower rapamycin doses lead to an increase in Akt 
phosphorylation, whereas higher doses diminish Akt phosphorylation.inhibition of signaling, due to mTOR/S6K-
mediated phosphorylation, and subsequent 
degradation of insulin response substrate-
1 (IRS-1). Rapamycin increases Akt activa-
tion in some cancer cell lines, and this has 
been attributed to the loss of this negative 
feedback loop, as demonstrated by an 
increase in IRS-1 levels and decrease 
in IRS-1 phosphorylation (O’Reilly et al., 
2006; Shi et al., 2005). This finding has lead 
to an interest in overcoming this feedback 
loop activation by using mTOR inhibitors in 
combination with antagonists of upstream 
signaling, such as IGF-IR inhibitors. In addi-
tion, it has been determined that mTOR, in 
a complex with rictor and GβL (mTORC2) 
directly phosphorylates Akt on Ser473 and 
facilitates Thr308 phosphorylation by PDK1 
(Hresko and Mueckler, 2005; Sarbassov et 
al., 2005). Prolonged rapamycin treatment 
has been shown to reduce the levels of 
mTORC2 below that necessary to maintain 
Akt activation in some cell lines, but not in 
others (Sarbassov et al., 2006). Thus, the 
effect of rapamycin on Akt activation may 
be dependent on the activity of upstream 
signaling pathways in the presence of rapa-
mycin, and on whether mTORC2 complex 
is maintained. It is unknown what predicts 
90 whether mTORC2 will be maintained in 
the presence of rapamycin. The regula-
tion of Akt phosphatases is also not well 
 understood.
The biological impact of mTOR inhibi-
tors may depend on (1) the cell type (EC 
versus TC), (2) the dosing regimen, and 
(3) the duration of treatment. The increase 
in Akt activation in tumor cells observed 
in this study is not simply a preclinical 
phenomenon, as an increase was also 
noted in tumor Akt phosphorylation in 
patients treated with the mTOR inhibi-
tor Everolimus (Novartis) (O’Reilly et al., 
2006). Although this paradoxical increase 
in Akt activation has not yet been shown 
to correlate with resistance to mTOR 
inhibitors, it has been presumed that this 
is an undesirable effect. This clearly rein-
forces the need for continued studies to 
elucidate the intricacies of this complex 
signaling pathway. A better understanding 
of how mTORC2 is maintained may help 
better prospectively predict which patients 
would have mTORC2 dissociation and a 
decrease in P-Akt.
The dose and schedule dependence 
of rapamycin activity is poorly understood. 
Phung and colleagues found that lower rapamycin doses led to an increase in EC 
Akt phosphorylation in vitro, whereas high-
er doses diminished Akt phosphorylation. 
In contrast, when Guba and colleagues 
initially described the antiangiogenic 
properties of rapamycin in a colon cancer 
model (Guba et al., 2002), they reported 
that a higher dose of rapamycin had an 
enhanced growth inhibitory effect early 
on, but tumors subsequently reentered 
a phase of rapid growth, while mice with 
tumors treated with relatively low doses 
showed tumor regression. In subsequent 
studies, this same group demonstrated 
that tumors were inhibited to the greatest 
degree by continuous infusion rather than 
bolus treatment (Guba et al., 2005). In a 
phase II clinical trial, there was no increase 
in response observed with dose escalation 
of the mTOR inhibitor temsirolimus (Atkins 
et al., 2004). Regardless, Phung’s data 
suggest that further work to optimize drug 
dose and schedule in order to maximize 
target inhibition, while also decreasing 
P-Akt levels in the tumor and endothelial 
cells, may be of value. It also underscores 
the importance of conducting correlative 
studies in clinical trials examining the effect 
of dose and schedule of mTOR inhibitors 
on signaling in the various compartments 
of tumors (i.e., vascular, stroma, tumor, 
etc.), provided these studies can be con-
ducted safely, are validated in preclinical 
models, and are associated with minimal/
no discomfort to our patients.
As demonstrated by the paradoxi-
cal increase in tumor cell Akt activation 
upon treatment with rapamycin, it must be 
recognized that, as with other therapies, 
tumors are likely to develop alternative/
resistance pathways to mediate survival 
and growth. However, identifying and elu-
cidating the signaling intermediates that 
regulate tumor vascular function will pro-
vide new avenues for therapeutic interven-
tion and predictive markers of efficacy.
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